One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry
Leslie R. Harrold(University of Massachusetts Chan Medical School), Mohamed Yassine(UCB Pharma (United States))
Cited by 39
Related Papers
AB0286 A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-To-Target Approach in the Clinical Care of Rheumatoid Arthritis Patients
|Annals of the Rheumatic Diseases|2015|5